Directive 98/8/EC of the European Parliament and of the Council (repealed)Show full title

ANNEX I U.K. LIST OF ACTIVE SUBSTANCES WITH REQUIREMENTS AGREED AT COMMUNITY LEVEL FOR INCLUSION IN BIOCIDAL PRODUCTSANNEX IALIST OF ACTIVE SUBSTANCES WITH REQUIREMENTS AGREED AT COMMUNITY LEVEL FOR INCLUSION IN LOW-RISK BIOCIDAL PRODUCTS

ANNEX IB LIST OF BASIC SUBSTANCES WITH REQUIREMENTS AGREED AT COMMUNITY LEVEL

ANNEX IIA U.K. COMMON CORE DATA SET FOR ACTIVE SUBSTANCESCHEMICAL SUBSTANCES

1. Dossiers on active substances are required to address at least all the points listed under ‘Dossier requirements’. Responses are required to be supported by data. The dossier requirements must be in line with technical development. U.K.

2. Information which is not necessary owing to the nature of the biocidal product or of its proposed uses need not be supplied. The same applies where it is not scientifically necessary or technically possible to supply the information. In such cases a justification, acceptable to the competent authority must be submitted. Such a justification may be the existence of a frame-formulation to which the applicant has the right of access. U.K.

Dossier requirements U.K.

I.

Applicant

II.

Identity of the active substance

III.

Physical and chemical properties of the active substance

IV.

Methods of detection and identification

V.

Effectiveness against target organisms and intended uses

VI.

Toxicological profile for man and animals including metabolism

VII.

Ecotoxicological profile including environmental fate and behaviour

VIII.

Measures necessary to protect man, animals and the environment

IX.

Classification and labelling

X.

Summary and evaluation of Sections II to IX

The following data will be required to support submission on the above points.

I. APPLICANT U.K.

1.1. Name and address, etc. U.K.

1.2. Active substance manufacturer (name, address, location of plant) U.K.

II. IDENTITY U.K.

2.1. Common name proposed or accepted by ISO and synonyms U.K.

2.2. Chemical name (IUPAC nomenclature) U.K.

2.3. Manufacturer's development code number(s) U.K.

2.4. CAS and EC numbers (if available) U.K.

2.5. Molecular and structural formula (including full details of any isomeric composition), molecular mass U.K.

2.6. Method of manufacture (syntheses pathway in brief terms) of active substance U.K.

2.7. Specification of purity of the active substance in g/kg or g/1, as appropriate U.K.

2.8. Identity of impurities and additives (e.g. stabilisers), together with the structural formula and the possible range expressed as g/kg or g/1, as appropriate U.K.

2.9. The origin of the natural active substance or the precursor(s) of the active substance, e.g. an extract of a flower U.K.

2.10. Exposure data in conformity with Annex VIIA to Directive 92/32/EEC(1). U.K.

III. PHYSICAL AND CHEMICAL PROPERTIES U.K.

3.1. Melting point, boiling point, relative density (¹) U.K.

3.2. Vapour pressure (in Pa)(¹) U.K.

3.3. Appearance (physical state, colour) (²) U.K.

3.4. Absorption spectra (UV/VIS, IR, NMR), and a mass spectrum, molar extinction at relevant wavelengths, where relevant (¹) U.K.

3.5. Solubility in water including effect of pH (5 to 9) and temperature on solubility, where relevant (¹) U.K.

3.6. Partition coefficient n-octanol/water including effect of pH (5 to 9) and temperature(¹) U.K.

3.7. Thermal stability, identity of relevant breakdown products U.K.

3.8. Flammability including auto-flammability and identity of combustion products U.K.

3.9. Flash-point U.K.

3.10. Surface tension U.K.

3.11. Explosive properties U.K.

3.12. Oxidising properties U.K.

3.13. Reactivity towards container material U.K.

IV. ANALYTICAL METHODS FOR DETECTION AND IDENTIFICATION U.K.

4.1. Analytical methods for the determination of pure active substance and, where appropriate, for relevant degradation products, isomers and impurities of the active substance and additives (e.g. stabilisers) U.K.

4.2. Analytical methods including recovery rates and the limits of determination for the active substance, and for residues thereof, and where relevant in/on the following: U.K.

(a)

Soil

(b)

Air

(c)

Water: the applicant should confirm that the substance itself and any of its degradation products which fall within the definition of pesticides given for parameter 55 in Annex I to Council Directive 80/778/EEC of 15 July 1980 relating to the quality of water intended for human consumption(2) can be estimated with adequate reliability at the MAC specified in that Directive for individual pesticides

(d)

Animal and human body fluids and tissues

V. EFFECTIVENESS AGAINST TARGET ORGANISMS AND INTENDED USES U.K.

5.1. Function, e.g. fungicide, rodenticide, insecticide, bactericide U.K.

5.2. Organism(s) to be controlled and products, organisms or objects to be protected U.K.

5.3. Effects on target organisms, and likely concentration at which the active substance will be used U.K.

5.4. Mode of action (including time delay) U.K.

5.5. Field of use envisaged U.K.

5.6. User: industrial, professional, general public (non-professional) U.K.

5.7. Information on the occurrence or possible occurrence of the development of resistance and appropriate management strategies U.K.

5.8. Likely tonnage to be placed on the market per year U.K.

VI. TOXICOLOGICAL AND METABOLIC STUDIES U.K.

6.1. Acute toxicity U.K.

For studies 6.1.1 to 6.1.3, substances other than gases shall be administered via at least two routes, one of which should be the oral route. The choice of the second route will depend on the nature of the substance and the likely route of human exposure. Gases and volatile liquids should be administered by the inhalation route.

6.1.1. Oral U.K.

6.1.2. Dermal U.K.

6.1.3. Inhalation U.K.

6.1.4. Skin and eye irritation (³) U.K.

6.1.5. Skin sensitisation U.K.

6.2. Metabolism studies in mammals. Basic toxicokinetics, including a dermal absorption study U.K.

For the following studies, 6.3 (where necessary), 6.4, 6.5, 6.7 and 6.8, the required route of administration is the oral route unless it can be justified that an alternative route is more appropriate

6.3. Short-term repeated dose toxicity (28 days) U.K.

This study is not required when a sub-chronic toxicity study is available in a rodent

6.4. Subchronic toxicity U.K.

90-day study, two species, one rodent and one non-rodent

6.5. Chronic toxicity (⁴) U.K.

One rodent and one other mammalian species

6.6. Mutagenicity studies U.K.

6.6.1. In-vitro gene mutation study in bacteria U.K.

6.6.2. In-vitro cytogenicity study in mammalian cells U.K.

6.6.3. In-vitro gene mutation assay in mammalian cells U.K.

6.6.4. If positive in 6.6.1, 6.6.2 or 6.6.3, then an in-vivo mutagenicity study will be required (bone marrow assay for chromosomal damage or a micronucleus test) U.K.

6.6.5. If negative in 6.6.4 but positive in-vitro tests then undertake a second in-vivo study to examine whether mutagenicity or evidence of DNA damage can be demonstrated in tissue other than bone marrow U.K.

6.6.6. If positive in 6.6.4 then a test to assess possible germ cell effects may be required U.K.

6.7. Carcinogenicity study (⁴) U.K.

One rodent and one other mammalian species. These studies may be combined with those in 6.5

6.8. Reproductive toxicity (⁵) U.K.

6.8.1. Teratogenicity test — rabbit and one rodent species U.K.

6.8.2. Fertility study — at least two generations, one species, male and female U.K.

6.9. Medical data in anonymous form U.K.

6.9.1. Medical surveillance data on manufacturing plant personnel if available U.K.

6.9.2. Direct observation, e.g. clinical cases, poisoning incidents if available U.K.

6.9.3. Health records, both from industry and any other available sources U.K.

6.9.4. Epidemiological studies on the general population, if available U.K.

6.9.5. Diagnosis of poisoning including specific signs of poisoning and clinical tests, if available U.K.

6.9.6. Sensitisation/allergenicity observations, if available U.K.

6.9.7. Specific treatment in case of an accident or poisoning: first aid measures, antidotes and medical treatment, if known U.K.

6.9.8. Prognosis following poisoning U.K.

6.10. Summary of mammalian toxicology and conclusions, including no observed adverse effect level (NOAEL), no observed effect level (NOEL), overall evaluation with regard to all toxicological data and any other information concerning the active substances. Where possible any suggested worker protection measures should be included in summary form U.K.

VII. ECOTOXICOLOGICAL STUDIES U.K.

7.1. Acute toxicity to fish U.K.

7.2. Acute toxicity to Daphnia magna U.K.

7.3. Growth inhibition test on algae U.K.

7.4. Inhibition to microbiological activity U.K.

7.5. Bioconcentration U.K.

Fate and behaviour in the environment

7.6. Degradation U.K.

7.6.1. Biotic U.K.

7.6.1.1. Ready biodegradability U.K.

7.6.1.2. Inherent biodegradability, where appropriate U.K.

7.6.2. Abiotic U.K.

7.6.2.1. Hydrolysis as a function of pH and identification of breakdown products U.K.

7.6.2.2. Phototransformation in water including identity of the products of transformation (¹) U.K.

7.7. Adsorption/desorption screening test U.K.

Where the results of this test indicate the need to do so, the test described in Annex IIIA Part XII.1 paragraph 1.2 shall be required, and/or the test described in Annex IIIA Part XII.2 paragraph 2.2

7.8. Summary of ecotoxicological effects and fate and behaviour in the environment U.K.

VIII. MEASURES NECESSARY TO PROTECT MAN, ANIMALS AND THE ENVIRONMENT U.K.

8.1. Recommended methods and precautions concerning handling, use, storage, transport or fire U.K.

8.2. In case of fire, nature of reaction products, combustion gases, etc. U.K.

8.3. Emergency measures in case of an accident U.K.

8.4. Possibility of destruction or decontamination following release in or on the following: (a) air (b) water, including drinking water (c) soil U.K.

8.5. Procedures for waste management of the active substance for industry or professional users U.K.

8.5.1. Possibility of reuse or recycling U.K.

8.5.2. Possibility of neutralisation of effects U.K.

8.5.3. Conditions for controlled discharge including leachate qualities on disposal U.K.

8.5.4. Conditions for controlled incineration U.K.

8.6. Observations on undesirable or unintended side-effects, e.g. on beneficial and other non-target organisms U.K.

IX. CLASSIFICATION AND LABELLING U.K.

Proposals including justification for the proposals for the classification and labelling of the active substance according to Directive 67/548/EEC

• Hazard symbol(s)

• Indications of danger

• Risk phrases

• Safety phrases

X. SUMMARY AND EVALUATION OF SECTIONS II TO IX U.K.

Notes U.K.

(¹) These data must be submitted for the purified active substance of stated specification. U.K.

(²) These data must be submitted for the active substance of stated specification. U.K.

(³) Eye irritation test shall not be necessary where the active substance has been shown to have potential corrosive properties. U.K.

(⁴) The long-term toxicity and carcinogenicity of an active substance may not be required where a full justification demonstrates that these tests are not necessary. U.K.

(⁵) If, in exceptional circumstances, it is claimed that such testing is unnecessary, that claim must be fully justified. U.K.

ANNEX IIB U.K. COMMON CORE DATA SET FOR BIOCIDAL PRODUCTSCHEMICAL PRODUCTS

1. Dossiers on biocidal products are required to address at least all the points listed under ‘Dossier requirements’. Responses are required to be supported by data. The dossier requirements must be in line with technical development. U.K.

2. Information which is not necessary owing to the nature of the biocidal product or of its proposed uses need not be supplied. The same applies where it is not scientifically necessary or technically possible to supply the information. In such cases a justification, acceptable to the competent authority must be submitted. Such a justification may be the existence of a frame-formulation to which the applicant has the right of access. U.K.

3. Information may be derived from existing data where a justification acceptable to the competent authority is provided. In particular, the provisions of Directive 88/379/EEC should be used wherever possible to minimise animal testing. U.K.

Dossier requirements U.K.

I.

Applicant

II.

Identity of the biocidal product

III.

Physical and chemical properties of the biocidal product

IV.

Methods for identification and analysis of the biocidal product

V.

Intended uses of the biocidal product and efficacy for these uses

VI.

Toxicology data for the biocidal product (additional to that for the active substance)

VII.

Ecotoxicology data for the biocidal product (additional to that for the active substance)

VIII.

Measures necessary to protect man, animals and the environment

IX.

Classification, packaging and labelling

X.

Summary and evaluation of Sections II to IX

The following data will be required to support submission on the above points.

I. APPLICANT U.K.

1.1. Name and address, etc. U.K.

1.2. Formulator of the biocidal product and the active substance(s) (names, addresses, including location of plant(s)) U.K.

II. IDENTITY U.K.

2.1. Trade name or proposed trade name, and manufacturer's development code number of the preparation, if appropriate U.K.

2.2. Detailed quantitative and qualitative information on the composition of the biocidal product, e.g. active substance(s), impurities, adjutants, inert components U.K.

2.3. Physical state and nature of the biocidal product, e.g. emulsifiable concentrate, wettable powder, solution U.K.

III. PHYSICAL, CHEMICAL AND TECHNICAL PROPERTIES U.K.

3.1. Appearance (physical state, colour) U.K.

3.2. Explosive properties U.K.

3.3. Oxidising properties U.K.

3.4. Flash-point and other indications of flammability or spontaneous ignition U.K.

3.5. Acidity/alkalinity and if necessary pH value (1 % in water) U.K.

3.6. Relative density U.K.

3.7. Storage stability — stability and shelf-life. Effects of light, temperature and humidity on technical characteristics of the biocidal product; reactivity towards container material U.K.

3.8. Technical characteristics of the biocidal product, e.g. wettability, persistent foaming, flowability, pourability and dustability U.K.

3.9. Physical and chemical compatibility with other products including other biocidal products with which its use is to be authorised U.K.

IV. METHODS OF IDENTIFICATION AND ANALYSIS U.K.

4.1. Analytical method for determining the concentration of the active substance(s) in the biocidal product U.K.

4.2. In so far as not covered by Annex IIA, paragraph 4.2, analytical methods including recovery rates and the limits of determination for toxicologically and ecotoxicologically relevant components of the biocidal product and/or residues thereof, where relevant in or on the following: U.K.

(a)

Soil

(b)

Air

(c)

Water (including drinking water)

(d)

Animal and human body fluids and tissues

(e)

Treated food or feedingstuffs

V. INTENDED USES AND EFFICACY U.K.

5.1. Product type and field of use envisaged U.K.

5.2. Method of application including description of system used U.K.

5.3. Application rate and if appropriate, the final concentration of the biocidal product and active substance in the system in which the preparation is to be used, e.g. cooling water, surface water, water used for heating purposes U.K.

5.4. Number and timing of applications, and where relevant, any particular information relating to geographical variations, climatic variations, or necessary waiting periods to protect man and animals U.K.

5.5. Function, e.g. fungicide, rodenticide, insecticide, bactericide U.K.

5.6. Pest organism(s) to be controlled and products, organisms or objects to be protected U.K.

5.7. Effects on target organisms U.K.

5.8. Mode of action (including time delay) in so far as not covered by Annex IIA, paragraph 5.4 U.K.

5.9. User: industrial, professsional, general public (non-professional) U.K.

Efficacy data

5.10. The proposed label claims for the product and efficacy data to support these claims, including any available standard protocols used, laboratory tests, or field trials, where appropriate U.K.

5.11. Any other known limitations on efficacy including resistance U.K.

VI. TOXICOLOGICAL STUDIES U.K.

6.1. Acute toxicity U.K.

For studies 6.1.1 to 6.1.3, biocidal products other than gases shall be administered via at least two routes, one of which should be the oral route. The choice of the second route will depend on the nature of the product and the likely route of human exposure. Gases and volatile liquids should be administered by the inhalation route

6.1.1. Oral U.K.

6.1.2. Dermal U.K.

6.1.3. Inhalation U.K.

6.1.4. For biocidal products that are intended to be authorised for use with other biocidal products, the mixture of products, where possible, shall be tested for acute dermal toxicity and skin and eye irritation, as appropriate U.K.

6.2. Skin and eye irritation(¹) U.K.

6.3. Skin sensitisation U.K.

6.4. Information on dermal absorption U.K.

6.5. Available toxicological data relating to toxicologically relevant non-active substances (i.e. substances of concern) U.K.

6.6. Information related to the exposure of the biocidal product to man and the operator U.K.

Where necessary, the test(s) described in Annex IIA, shall be required for the toxicologically relevant non-active substances of the preparation

VII. ECOTOXICOLOGICAL STUDIES U.K.

7.1. Foreseeable routes of entry into the environment on the basis of the use envisaged U.K.

7.2. Information on the ecotoxicology of the active substance in the product, where this cannot be extrapolated from the information on the active substance itself U.K.

7.3. Available ecotoxicological information relating to exotoxicological relevant non-active substances (i.e. substances of concern), such as information from safety data sheets U.K.

VIII. MEASURES TO BE ADOPTED TO PROTECT MAN, ANIMALS AND THE ENVIRONMENT U.K.

8.1. Recommended methods and precautions concerning handling, use, storage, transport or fire U.K.

8.2. Specific treatment in case of an accident, e.g. first-aid measures, antidotes, medical treatment if available; emergency measures to protect the environment; in so far as not covered by Annex IIA, paragraph 8.3 U.K.

8.3. Procedures, if any, for cleaning application equipment U.K.

8.4. Identity of relevant combustion products in cases of fire U.K.

8.5. Procedures for waste management of the biocidal product and its packaging for industry, professional users and the general public (non-professional users), e.g. possibility of reuse or recycling, neutralisation, conditions for controlled discharge, and incineration U.K.

8.6. Possibility of destruction or decontamination following release in or on the following: U.K.

(a)

Air

(b)

Water, including drinking water

(c)

Soil

8.7. Observations on undesirable or unintended side-effects, e.g. on beneficial and other non-target organisms U.K.

8.8. Specify any repellents or poison control measures included in the preparation that are present to prevent action against non-target organisms U.K.

IX. CLASSIFICATION, PACKAGING AND LABELLING U.K.

• Proposals for packaging and labelling

• Proposals for safety-data sheets, where appropriate

• Justification for the classification and labelling according to the principles of Article 20 of this Directive

  • Hazard symbol(s)

  • Indications of danger

  • Risk phrases

  • Safety phrases

  • Packaging (type, materials, size, etc.), compatibility of the preparation with proposed packaging materials to be included

X. SUMMARY AND EVALUATION OF SECTIONS II TO IX U.K.

Notes U.K.

(¹) Eye-irritation test shall not be necessary where the biocidal product has been shown to have potential corrosive properties. U.K.

ANNEX IIIA U.K. ADDITIONAL DATA SET FOR ACTIVE SUBSTANCESCHEMICAL SUBSTANCES

1. Dossiers on active substances are required to address at least all the points listed under ‘Dossier requirements’. Responses are required to be supported by data. The dossier requirements must be in line with technical development. U.K.

2. Information which is not necessary owing to the nature of the biocidal product or of its proposed uses need not be supplied. The same applies where it is not scientifically necessary or technically possible to supply the information. In such cases a justification, acceptable to the competent authority must be submitted. Such a justification may be the existence of a frame-formulation to which the applicant has the right of access. U.K.

III. PHYSICAL AND CHEMICAL PROPERTIES U.K.

1. Solubility in organic solvents, including effect of temperature on solubility (¹) U.K.

2. Stability in organic solvents used in biocidal products and identity of relevant breakdown products (²) U.K.

IV. ANALYTICAL METHODS FOR DETECTION AND IDENTIFICATION U.K.

1. Analytical methods including recovery rates and the limits of determination for the active substance, and for residues thereof, in/on food or feedstuffs and other products where relevant U.K.

VI. TOXICOLOGICAL AND METABOLIC STUDIES U.K.

1. Neurotoxicity study U.K.

If the active substance is an organophosphorus compound or if there are any other indications that the active substance may have neurotoxic properties then neurotoxicity studies will be required. The test species is the adult hen unless another test species is justified to be more appropriate. If appropriate, delayed neurotoxicity tests will be required. If anticholine esterase activity is detected a test for response to reactivating agents should be considered

2. Toxic effects on livestock and pets U.K.

3. Studies related to the exposure of the active substance to humans U.K.

4. Food and feedingstuffs U.K.

If the active substance is to be used in preparations for use where food for human consumption is prepared, consumed or stored, or where feedingstuff for livestock is prepared, consumed or stored the tests referred to in Section XI, part 1 shall be required

5. If any other tests related to the exposure of the active substance to humans, in its proposed biocidal products, are considered necessary, then the test(s) referred to in Section XI, part 2 shall be required U.K.

6. If the active substance is to be used in products for action against plants then tests to assess toxic effects of metabolites from treated plants, if any, where different from those identified in animals shall be required U.K.

7. Mechanistic study — any studies necessary to clarify effects reported in toxicity studies U.K.

VII. ECOTOXICOLOGICAL STUDIES U.K.

1. Acute toxicity test on one other, non-aquatic, non-target organism U.K.

2. If the results of the ecotoxicological studies and the intended use(s) of the active substance indicate a danger for the environment then the tests described in Sections XII and XIII shall be required U.K.

3. If the result of the test in paragraph 7.6.1.2 of Annex IIA is negative and if the likely route of disposal of the active substance is by sewage treatment then the test described in Section XIII, part 4.1 shall be required U.K.

4. Any other biodegradability tests that are relevant from the results in paragraphs 7.6.1.1 and 7.6.1.2 of Annex IIA U.K.

5. Phototransformation in air (estimation method), including identification of breakdown products (¹) U.K.

6. If the results from paragraphs 7.6.1.2 in Annex IIA or from paragraph 4, above, indicate the need to do so, or the active substance has an overall low or absent abiotic degradation, then the tests described in Section XII, part 1.1, part 2.1 and, where appropriate, part 3 shall be required U.K.

VIII. MEASURES NECESSARY TO PROTECT HUMANS, ANIMALS AND THE ENVIRONMENT U.K.

1. Identification of any substances falling within the scope of List I or List II of the Annex to Directive 80/68/EEC on the protection of groundwater against pollution caused by certain dangerous substances(3) U.K.

Notes U.K.

(¹) These data must be submitted for the purified active substance of stated specification. U.K.

(²) These data must be submitted for the active substance of stated specification. U.K.

XI. FURTHER HUMAN HEALTH-RELATED STUDIES U.K.

1. Food and feedingstuffs studies U.K.

1.1. Identification of degradation and reaction products and of metabolites of the active substance in treated or contaminated foods or feedstuffs U.K.

1.2. Behaviour of the residue of the active substance, its degradation products and, where relevant, its metabolites on the treated or contaminated food or feedstuffs including the kinetics of disappearance U.K.

1.3. Overall material balance for the active substance. Sufficient residue data from supervised trials to demonstrate that residues likely to arise from the proposed use would not be of concern for human or animal health U.K.

1.4. Estimation of potential or actual exposure of the active substance to humans through diet and other means U.K.

1.5. If residues of the active substance remain on feedingstuffs for a significant period of time then feeding and metabolism studies in livestock shall be required to permit evaluation of residues in food of animal origin U.K.

1.6. Effects of industrial processing and/or domestic preparation on the nature and magnitude of residues of the active substance U.K.

1.7. Proposed acceptable residues and the justification of their acceptability U.K.

1.8. Any other available information that is relevant U.K.

1.9. Summary and evaluation of data submitted under 1.1 to 1.8 U.K.

2. Other test(s) related to the exposure to humans U.K.

Suitable test(s) and a reasoned case will be required

XII. FURTHER STUDIES ON FATE AND BEHAVIOUR IN THE ENVIRONMENT U.K.

1. Fate and behaviour in soil U.K.

1.1. Rate and route of degradation including identification of the processes involved and identification of any metabolites and degradation products in at least three soil types under appropriate conditions U.K.

1.2. Absorption and desorption in at least three soil types and, where relevant, absorption and desorption of metabolites and degradation products U.K.

1.3. Mobility in at least three soil types and where relevant mobility of metabolites and degradation products U.K.

1.4. Extent and nature of bound residues U.K.

2. Fate and behaviour in water U.K.

2.1. Rate and route of degradation in aquatic systems (as far as is not covered by Annex IIA, paragraph 7.6) including identification of metabolites and degradation products U.K.

2.2. Absorption and desorption in water (soil sediment systems) and, where relevant, absorption and desorption of metabolites and degradation products U.K.

3. Fate and behaviour in air U.K.

If the active substance is to be used in preparations for fumigants, if it is to be applied by a spray method, if it is volatile, or if any other information indicates that this is relevant, then the rate and route of degradation in air shall be determined as far as is not covered by Section VII, part 5

4. Summary and evaluation of parts 1, 2 and 3 U.K.

XIII. FURTHER ECOTOXICOLOGICAL STUDIES U.K.

1. Effects on birds U.K.

1.1. Acute oral toxicity — this need not be done if an avian species was selected for study in Section VII, part 1 U.K.

1.2. Short-term toxicity — eight-day dietary study in at least one species (other than chickens) U.K.

1.3. Effects on reproduction U.K.

2. Effects on aquatic organisms U.K.

2.1. Prolonged toxicity to an appropriate species of fish U.K.

2.2. Effects on reproduction and growth rate on an appropriate species of fish U.K.

2.3. Bioaccumulation in an appropriate species of fish U.K.

2.4. Daphnia magna reproduction and growth rate U.K.

3. Effects on other non-target organisms U.K.

3.1. Acute toxicity to honeybees and other beneficial arthropods, e.g. predators. A different test organism shall be chosen from that used in Section VII, part 1 U.K.

3.2. Toxicity to earthworms and to other soil non-target macro-organisms U.K.

3.3. Effects on soil non-target micro-organisms U.K.

3.4. Effects on any other specific, non-target organisms (flora and fauna) believed to be at risk U.K.

4. Other effects U.K.

4.1. Activated sludge respiration inhibition test U.K.

5. Summary and evaluation of parts 1, 2, 3 and 4 U.K.

ANNEX IIIB U.K. ADDITIONAL DATA SET FOR BIOCIDAL PRODUCTSCHEMICAL PRODUCTS

1. Dossiers on biocidal products are required to address at least all the points listed under ‘Dossier requirements’. Responses are required to be supported by data. The dossier requirements must be in line with technical development. U.K.

2. Information which is not necessary owing to the nature of the biocidal product or of its proposed uses need not be supplied. The same applies where it is not scientifically necessary or technically possible to supply the information. In such cases a justification, acceptable to the competent authority must be submitted. Such a justification may be the existence of a frame-formulation to which the applicant has the right of access. U.K.

3. Information may be derived from existing data where a justification acceptable to the competent authority is provided. In particular, the provisions of Directive 88/379/EEC should be used wherever possible to minimise animal testing. U.K.

XI. FURTHER HUMAN HEALTH-RELATED STUDIES U.K.

1. Food and feedingstuffs studies U.K.

1.1. If residues of the biocidal product remain on feedingstuffs for a significant period of time, then feeding and metabolism studies in livestock shall be required to permit evaluation of residues in food of animal origin U.K.

1.2. Effects of industrial processing and/or domestic preparation on the nature and magnitude of residues of the biocidal product U.K.

2. Other test(s) related to the exposure to humans U.K.

Suitable test(s) and a reasoned case will be required for the biocidal product

XII. FURTHER STUDIES ON FATE AND BEHAVIOUR IN THE ENVIRONMENT U.K.

1. Where relevant all the information required in Annex IIIA, Section XII U.K.

2. Testing for distribution and dissipation in the following: U.K.

(a)

Soil

(b)

Water

(c)

Air

Test requirements 1 and 2 above are applicable only to ecotoxicologically relevant components of the biocidal product

XIII. FURTHER ECOTOXICOLOGICAL STUDIES U.K.

1. Effects on birds U.K.

1.1. Acute oral toxicity, if not already done in accordance with Annex IIB, Section VII U.K.

2. Effects on aquatic organisms U.K.

2.1. In case of application on, in, or near to surface waters U.K.

2.1.1. Particular studies with fish and other aquatic organisms U.K.

2.1.2. Residue data in fish concerning the active substance and including toxicologically relevant metabolites U.K.

2.1.3. The studies referred to in Annex IIIA, Section XIII, parts 2.1, 2.2, 2.3 and 2.4 may be required for relevant components of the biocidal product U.K.

2.2. If the biocidal product is to be sprayed near to surface waters then an overspray study may be required to assess risks to aquatic organisms under field conditions U.K.

3. Effects on other non-target organisms U.K.

3.1. Toxicity to terrestrial vertebrates other than birds U.K.

3.2. Acute toxicity to honeybees U.K.

3.3. Effects on beneficial arthropods other than bees U.K.

3.4. Effects on earthworms and other soil non-target macro-organisms, believed to be at risk U.K.

3.5. Effects on soil non-target micro-organisms U.K.

3.6. Effects on any other specific, non-target organisms (flora and fauna) believed to be at risk U.K.

3.7. If the biocidal product is in the form of bait or granules U.K.

3.7.1. Supervised trials to assess risks to non-target organisms under field conditions U.K.

3.7.2. Studies on acceptance by ingestion of the biocidal product by any non-target organisms thought to be at risk U.K.

4. Summary and evaluation of parts 1, 2, and 3 U.K.

ANNEX IVA U.K. DATA SET FOR ACTIVE SUBSTANCESFUNGI, MICRO-ORGANISMS AND VIRUSES

1. Dossiers on active organisms are required to address at least all the points listed under ‘Dossier requirements’ below. Responses are required to be supported by data. The dossier requirements must be in line with technical development. U.K.

2. Information which is not necessary owing to the nature of the biocidal product or of its proposed uses need not be supplied. The same applies where it is not scientifically necessary or technically possible to supply the information. In such cases, a justification, acceptable to the competent authority must be submitted. Such a justification may be the existence of a frame-formulation to which the applicant has the right of access. U.K.

Dossier requirements U.K.

I.

Applicant details

II.

Identity of the active organism

III.

Source of active organism

IV.

Methods of detection and identification

V.

Biological properties of active organism including pathogenicity and infectivity for target and non-target organisms including man

VI.

Effectiveness and intended uses

VII.

Toxicological profile for man and animals including metabolism of toxins

VIII.

Ecotoxicological profile including environmental fate and behaviour of the organisms and of toxins it produces

IX.

Measures necessary to protect man, non-target organisms and the environment

X.

Classification and labelling

XI.

Summary and evaluation of Sections II to X

The following data will be required to support submissions on the above points.

I. APPLICANT U.K.

1.1. Applicant (name, address, etc.) U.K.

1.2. Manufacturer (name, address, plant location) U.K.

II. IDENTITY OF THE ORGANISM U.K.

2.1. Common name of organism (including alternative and superseded names) U.K.

2.2. Taxonomic name and strain indicating whether it is a stock variant or a mutant strain; for viruses, taxonomic designation of the agent, serotype, strain or mutant U.K.

2.3. Collection and culture reference number where the culture is deposited U.K.

2.4. Methods, procedures and criteria used to establish the presence and identity of the organism (e.g. morphology, biochemistry, serology, etc.) U.K.

III. SOURCE OF THE ORGANISM U.K.

3.1. Occurrence in nature or otherwise U.K.

3.2. Isolation methods for organism or active strain U.K.

3.3. Culture methods U.K.

3.4. Production methods including details of containment and procedure to maintain quality and ensure a uniform source of active organism. For mutant strains detailed information should be provided on production and isolation, together with all known differences between the mutant strains and parent and naturally occurring strains U.K.

3.5. Composition of the final active organism material i.e. nature, purity, identity, properties, content of any impurities and extraneous organisms U.K.

3.6. Methods to prevent contamination of seed stock and loss of virulence of seed stock U.K.

3.7. Procedures for waste management U.K.

IV. METHODS OF DETECTION AND IDENTIFICATION U.K.

4.1. Methods for establishing the presence and identity of the organism U.K.

4.2. Methods for establishing the identity and purity of seed stock from which batches are produced and results obtained, including information on variability U.K.

4.3. Methods to show the microbiological purity of the final product and showing that contaminants have been controlled to an acceptable level, the results obtained and information on variability U.K.

4.4. Methods used to show that there are no human or other mammalian pathogens as contaminants in the active agent, including in the case of protozoa and fungi, the effects of temperature (35 ^oC and other relevant temperatures) U.K.

4.5. Methods to determine viable and non-viable (e.g. toxins) residues in or on treated products, foodstuffs, feedingstuffs, animal and human body fluids and tissues, soil, water and air, where relevant U.K.

V. BIOLOGICAL PROPERTIES OF THE ORGANISM U.K.

5.1. History of the organism and its uses including as far as is known its general natural history and, if relevant, its geographical distribution U.K.

5.2. Relationship to existing pathogens of vertebrates, invertebrates, plants or other organisms U.K.

5.3. Effects on target organism. Pathogenicity or kind of antagonism to the host. Details of host specificity range should be included U.K.

5.4. Transmissibility, infective dose and mode of action including information on presence, absence or production of toxins with, if appropriate, information on their nature, identity, chemical structure and stability and potency U.K.

5.5. Possible effects on non-target organisms closely related to the target organism including infectivity, pathogenicity, and transmissibility U.K.

5.6. Transmissibility to other non-target organisms U.K.

5.7. Any other biological effects on non-target organisms when properly used U.K.

5.8. Infectivity and physical stability when properly used U.K.

5.9. Genetic stability under environmental conditions of proposed use U.K.

5.10. Any pathogenicity and infectivity to man and animals under conditions of immunosuppression U.K.

5.11. Pathogenicity and infectivity for known parasites/predators of the target species U.K.

VI. EFFECTIVENESS AND INTENDED USES U.K.

6.1. Harmful organisms controlled and materials, substances, organisms or products to be treated or protected U.K.

6.2. Uses envisaged (e.g. insecticide, disinfectant, anti-fouling product, etc.) U.K.

6.3. Information or observations on undesirable or unintended side effects U.K.

6.4. Information on the occurrence or possible occurrence of the development of resistance and possible management strategies to deal with this U.K.

6.5. Effects on target organisms U.K.

6.6. Category of user U.K.

VII. TOXICOLOGICAL AND METABOLIC STUDIES U.K.

7.1. Acute toxicity U.K.

In cases where a single dose is not appropriate, a set of range finding tests must be carried out to reveal highly toxic agents and infectivity

1.

oral

2.

dermal

3.

inhalation

4.

skin and where necessary eye irritation

5.

skin sensitisation and, where necessary, respiratory sensitisation and

6.

for viruses and viroids, cell culture studies using purified infective virus and primary cell cultures of mammalian, avian and fish cells

7.2. Sub-chronic toxicity U.K.

40-day study, two species, one rodent, one non-rodent

1.

oral administration

2.

other routes (inhalation, dermal) as appropriate and

3.

for viruses and viroids test for infectivity carried out by bio assay or on a suitable cell culture at least seven days after administration to test animals

7.3. Chronic toxicity U.K.

Two species, rodent and one other mammal, oral administration unless another route is more appropriate

7.4. Carcinogenicity study U.K.

May be combined with studies in 6.3. One rodent and one other mammal

7.5. Mutagenicity studies U.K.

As specified in Annex IIA, Section VI, part 6.6

7.6. Reproductive toxicity U.K.

Teratogenicity test — rabbit and one rodent species. Fertility study — one species, minimum of two generations, male and female

7.7. Metabolism studies U.K.

Basic toxicokinetics, absorption (including dermal absorption) distribution and excretion in mammals including elucidation of metabolic pathways

7.8. Neurotoxicity studies: required where there is any indication of anticholinerterase activity or other neurotoxic effects. Delayed neurotoxicity tests using adult hens should be performed where appropriate U.K.

7.9. Immunotoxicity studies (e.g. allergenicity) U.K.

7.10. Incidental exposure studies: required where the active substance will be in products for use where human food or animal feedingstuffs are prepared, consumed or stored and where humans, livestock or pets are likely to be exposed to treated areas or materials U.K.

7.11. Human exposure data including: U.K.

1.

Medical data in anonymous form (if available)

2.

Health records, medical surveillance data on manufacturing plants personnel (if available)

3.

Epidemiological data (if available)

4.

Poisoning incidents data

5.

Poisoning diagnosis (signs, symptoms) including details of any analytical tests

6.

Proposed treatment of poisoning and prognoses

7.12. Summary of mammalian toxicology — conclusions (including NOAEL, NOEL and if appropriate ADI), overall evaluation with regard to all toxicological, pathogenicity and infectivity data and any other information concerning the active organism. Where possible suggested user protection measures should be included in summary form U.K.

VIII. ECOTOXICOLOGICAL STUDIES U.K.

8.1. Acute toxicity to fish U.K.

8.2. Acute toxicity to Daphnia magna U.K.

8.3. Effects on algae growth (inhibition test) U.K.

8.4. Acute toxicity on one other, non-aquatic, non-target organism U.K.

8.5. Pathogenicity and infectivity for honeybees and earthworms U.K.

8.6. Acute toxicity and/or pathogenicity and infectivity for other non-target organisms believed to be at risk U.K.

8.7. Effects (if any) on other flora and fauna U.K.

8.8. In cases where toxins are produced, data as outlined in Annex IIA, Section VII, parts 7.1 to 7.5 should be produced U.K.

Fate and behaviour in the environment

8.9. Spread, mobility, multiplication and persistence in air, soil and water U.K.

8.10. In cases where toxins are produced, data as outlined in Annex IIA, Section VII, parts 7.6 to 7.8 U.K.

IX. MEASURES NECESSARY TO PROTECT HUMANS, NON-TARGET ORGANISMS AND THE ENVIRONMENT U.K.

9.1. Methods and precautions to be taken for storage, handling, transport and use; or in the event of fire or other likely incident U.K.

9.2. Any circumstances or environmental conditions under which the active organism should not be used U.K.

9.3. The possibility of rendering the active organism non-infective and any method for doing this U.K.

9.4. Consequences of the contamination of air, soil and water, particularly drinking water U.K.

9.5. Emergency measures in case of accident U.K.

9.6. Procedures for waste management of the active organism including leachate qualities on disposal U.K.

9.7. Possibility of destruction or decontamination following release in or into the following: air, water, soil, others if appropriate U.K.

X. CLASSIFICATION AND LABELLING U.K.

Proposals for allocation to one of the risk groups outlined in Article 2(d) of Directive 90/679/EEC with justifications for the proposal together with indications on the need for products to carry the biohazard sign specified in Annex II to Directive 90/679/EEC

XI. SUMMARY AND EVALUATION OF SECTIONS II TO X U.K.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

ANNEX IVB U.K. DATA SET FOR BIOCIDAL PRODUCTSFUNGI, MICRO-ORGANISMS AND VIRUSES

1. Dossiers on biocidal products are required to address at least all the points listed under ‘Dossier requirements’. Responses are required to be supported by data. The dossier requirements must be in line with technical development. U.K.

2. Information which is not necessary owing to the nature of the biocidal product or of its proposed uses need not be supplied. The same applies where it is not scientifically necessary or technically possible to supply the information. In such cases, a justification, acceptable to the competent authority must be submitted. Such a justification may be the existence of a frame-formulation to which the applicant has the right of access. U.K.

3. Information may be derived from existing data where a justification acceptable to the competent authority is provided. In particular, the provisions of Directive 88/379/EEC should be used wherever possible to minimise animal testing. U.K.

Dossier requirements U.K.

I.

Applicant

II.

Identity and composition of the biocidal product

III.

Technical properties of the biocidal product and any biocidal properties additional to those of the active organism

IV.

Methods for identification and analysis of the biocidal product

V.

Intended uses and efficacy for those uses

VI.

Toxicological information (additional to that for the active organism)

VII.

Ecotoxicological information (additional to that for the active organism)

VIII.

Measures to be adopted to protect humans, non-target organisms and the environment

IX.

Classification, packaging and labelling of the biocidal product

X.

Summary of Sections II to IX

The following data will be required to support submission on the above points.

I. APPLICANT U.K.

1.1. Name and address, etc. U.K.

1.2. Manufacturers of biocidal products and active organisms including location of plants U.K.

II. IDENTITY OF BIOCIDAL PRODUCT U.K.

2.1. Trade name or proposed trade name and manufacturer's development code number for biocidal product, if appropriate U.K.

2.2. Detailed quantitative and qualitative information on the composition of the biocidal product (active organisms, inert components, extraneous organisms, etc.) U.K.

2.3. Physical state and nature of the biocidal product (emulsifiable concentrate, wettable powder, etc.) U.K.

2.4. Concentration of active organism in material used U.K.

III. TECHNICAL AND BIOLOGICAL PROPERTIES U.K.

3.1. Appearance (colour and odour) U.K.

3.2. Storage — stability and shelf-life. Effects of temperature, method of packaging and storage, etc. on retention of biological activity U.K.

3.3. Methods for establishing storage and shelf-life stability U.K.

3.4. Technical characteristics of the biocidal product U.K.

3.4.1. Wettability U.K.

3.4.2. Persistent foaming U.K.

3.4.3. Suspensibility and suspension stability U.K.

3.4.4. Wet sieve test and dry sieve test U.K.

3.4.5. Particle size distribution, content of dust/fines, attrition and friability U.K.

3.4.6. In the case of granules, sieve test and indications of weight distribution of the granules, at least of the fraction with particle sizes bigger than 1 mm U.K.

3.4.7. Content of active substance in or on bait particles, granules or treated material U.K.

3.4.8. Emulsifiability, re-emulsifiability, emulsion stability U.K.

3.4.9. Flowability, pourability and dustability U.K.

3.5. Physical and chemical compatibility with other products including biocidal products with which its use is to be authorised U.K.

3.6. Wetting, adherence and distribution following application U.K.

3.7. Any changes to biological properties of the organism is a result of formulation. In particular changes in pathogenicity on infectivity U.K.

IV. METHOD FOR IDENTIFICATION AND ANALYSIS U.K.

4.1. Analytical methods for determining the composition of the biocidal product U.K.

4.2. Methods for determining residues (e.g. biotest) U.K.

4.3. Methods used to show microbiological purity of the biocidal product U.K.

4.4. Methods used to show the biocidal product to be free from any human and other mammalian pathogens or, if need be, from pathogens harmful to non-target organisms and the environment U.K.

4.5. Techniques used to ensure a uniform product and assay methods for its standardisation U.K.

V. INTENDED USES AND EFFICACY FOR THESE USES U.K.

5.1. Use U.K.

Product-type (e.g. wood preservative, insecticide, etc.)

5.2. Details of intended use, (e.g. types of harmful organism controlled, materials to be treated, etc.) U.K.

5.3. Application rate U.K.

5.4. Where necessary, in the light of the test results, any specific circumstances or environmental conditions under which the product may or may not be used U.K.

5.5. Method of application U.K.

5.6. Number and timing of applications U.K.

5.7. Proposed instructions for use U.K.

Efficacy data

5.8. Preliminary range-finding tests U.K.

5.9. Field experimentation U.K.

5.10. Information on the possible occurrence of the development of resistance U.K.

5.11. Effects on the quality of materials or products treated U.K.

VI. TOXICITY INFORMATION ADDITIONAL TO THAT REQUIRED FOR THE ACTIVE ORGANISM U.K.

6.1. Oral single dose U.K.

6.2. Percutaneous single dose U.K.

6.3. Inhalation U.K.

6.4. Skin and where relevant eye irritation U.K.

6.5. Skin sensitisation U.K.

6.6. Available toxicological data relating to non-active substances U.K.

6.7. Operator exposure U.K.

6.7.1. Percutaneous absorption/inhalation depending on formulation and method of application U.K.

6.7.2. Likely operator exposure under field conditions, including where relevant quantitative analysis of operator exposure U.K.

VII. ECOTOXICITY INFORMATION ADDITIONAL TO THAT REQUIRED FOR THE ACTIVE ORGANISM U.K.

7.1. Observations concerning undesirable or unintended side-effects, e.g. on beneficial and other non-target organisms or persistence in the environment U.K.

VIII. MEASURES TO BE ADOPTED TO PROTECT MAN, NON-TARGET ORGANISMS AND THE ENVIRONMENT U.K.

8.1. Recommended methods and precautions concerning handling, storage, transport and use U.K.

8.2. Re-entry periods, necessary waiting periods or other precautions to protect humans and animals U.K.

8.3. Emergency measures in case of an accident U.K.

8.4. Procedures for destruction or decontamination of the biocidal product and its packaging U.K.

IX. CLASSIFICATION, PACKAGING AND LABELLING U.K.

9.1. Proposals including justification for the classification, packaging and labelling U.K.

I.

With regard to non-biological components of the product in accordance with Directive 88/379/EEC

• Hazard symbol(s)

• Indications of danger

• Risk phrases

• Safety phrases

II.

With regard to the active organisms labelling with the appropriate risk group as outlined in Article 2(d) of Directive 90/679/EEC together with the biohazard sign specified in that Directive if appropriate

9.2. Packaging (type, materials, size, etc.), compatibility of the biocidal product with proposed packaging materials U.K.

9.3. Specimens of proposed packaging U.K.

X. SUMMARY OF SECTIONS II to IX U.K.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

ANNEX V U.K. BIOCIDAL PRODUCT-TYPES AND THEIR DESCRIPTIONS AS REFERRED TO IN ARTICLE 2(1)(a) OF THIS DIRECTIVE

These product-types exclude products where they are covered by the Directives mentioned in Article 1(2) of this Directive for the purposes of these Directives and their subsequent modifications.

MAIN GROUP 1: Disinfectants and general biocidal products U.K.

These product types exclude cleaning products that are not intended to have a biocidal effect, including washing liquids, powders and similar products.

Product-type 1: Human hygiene biocidal products U.K.

Products in this group are biocidal products used for human hygiene purposes.

Product-type 2: Private area and public health area disinfectants and other biocidal products U.K.

Products used for the disinfection of air, surfaces, materials, equipment and furniture which are not used for direct food or feed contact in private, public and industrial areas, including hospitals, as well as products used as algaecides.

Usage areas include, inter alia, swimming pools, aquariums, bathing and other waters; air-conditioning systems; walls and floors in health and other institutions; chemical toilets, waste water, hospital waste, soil or other substrates (in playgrounds).

Product-type 3: Veterinary hygiene biocidal products U.K.

Products in this group are biocidal products used for veterinary hygiene purposes including products used in areas in which animals are housed, kept or transported.

Product-type 4: Food and feed area disinfectants U.K.

Products used for the disinfection of equipment, containers, consumption utensils, surfaces or pipework associated with the production, transport, storage or consumption of food, feed or drink (including drinking water) for humans and animals.

Product-type 5: Drinking water disinfectants U.K.

Products used for the disinfection of drinking water (for both humans and animals).

MAIN GROUP 2: Preservatives U.K.

Product-type 6: In-can preservatives U.K.

Products used for the preservation of manufactured products, other than foodstuffs or feedingstuffs, in containers by the control of microbial deterioration to ensure their shelf life.

Product-type 7: Film preservatives U.K.

Products used for the preservation of films or coatings by the control of microbial deterioration in order to protect the initial properties of the surface of materials or objects such as paints, plastics, sealants, wall adhesives, binders, papers, art works.

Product-type 8: Wood preservatives U.K.

Products used for the preservation of wood, from and including the saw-mill stage, or wood products by the control of wood-destroying or wood-disfiguring organisms.

This product type includes both preventive and curative products.

Product-type 9: Fibre, leather, rubber and polymerised materials preservatives U.K.

Products used for the preservation of fibrous or polymerised materials, such as leather, rubber or paper or textile products and rubber by the control of microbiological deterioration.

Product-type 10: Masonry preservatives U.K.

Products used for preservation and remedial treatment of masonry or other construction materials other than wood by the control of microbiological and algal attack.

Product-type 11: Preservatives for liquid-cooling and processing systems U.K.

Products used for the preservation of water or other liquids used in cooling and processing systems by the control of harmful organisms such as microbes, algae and mussels.

Products used for the preservation of drinking water are not included in this product type.

Product-type 12: Slimicides U.K.

Products used for the prevention or control of slime growth on materials, equipment and structures, used in industrial processes, e.g. on wood and paper pulp, porous sand strata in oil extraction.

Product-type 13: Metalworking-fluid preservatives U.K.

Products used for the preservation of metalworking fluids by the control of microbial deterioration.

MAIN GROUP 3: Pest control U.K.

Product-type 14: Rodenticides U.K.

Products used for the control of mice, rats or other rodents.

Product-type 15: Avicides U.K.

Products used for the control of birds.

Product-type 16: Molluscicides U.K.

Products used for the control of molluscs.

Product-type 17: Piscicides U.K.

Products used for the control of fish; these products exclude products for the treatment of fish diseases.

Product-type 18: Insecticides, acaricides and products to control other arthropods Products used for the control of arthropods (e.g. insects, arachnids and crustaceans). U.K.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Product-type 19: Repellents and attractants U.K.

Products used to control harmful organisms (invertebrates such as fleas, vertebrates such as birds), by repelling or attracting, including those that are used for human or veterinary hygiene either directly or indirectly.

MAIN GROUP 4: Other biocidal products U.K.

Product-type 20: Preservatives for food or feedstocks U.K.

Products used for the preservation of food or feedstocks by the control of harmful organisms.

Product-type 21: Antifouling products U.K.

Products used to control the growth and settlement of fouling organisms (microbes and higher forms of plant or animal species) on vessels, aquaculture equipment or other structures used in water.

Product-type 22: Embalming and taxidermist fluids U.K.

Products used for the disinfection and preservation of human or animal corpses, or parts thereof.

Product-type 23: Control of other vertebrates U.K.

Products used for the control of vermin.

ANNEX VI U.K. COMMON PRINCIPLES FOR THE EVALUATION OF DOSSIERS FOR BIOCIDAL PRODUCTS

CONTENTS U.K.

Definitions

Introduction

Evaluation

• General principles

• Effects on humans

• Effects on animals

• Effects on the environment

• Unacceptable effects

• Efficacy

• Summary

Decision-making

• General principles

• Effects on humans

• Effects on animals

• Effects on the environment

• Unacceptable effects

• Efficacy

• Summary

Overall integration of conclusions

DEFINITIONS U.K.

(a)

Hazard identification

This is the identification of the adverse effects which a biocidal product has an inherent capacity to cause.

(b)

Dose (concentration) — response (effect) assessment

This is the estimate of the relationship between the dose, or level of exposure, of an active substance or substance of concern in a biocidal product and the incidence and severity of an effect.

(c)

Exposure assessment

This is the determination of the emissions, pathways and rates of movement of an active substance or a substance of concern in a biocidal product and its transformation or degradation in order to estimate the concentration/doses to which human populations, animals or environmental compartments are or may be exposed.

(d)

Risk characterisation

This is the estimation of the incidence and severity of the adverse effects likely to occur in a human population, animals or environmental compartments due to actual or predicted exposure to any active substance or substance of concern in a biocidal product. This may include ‘risk estimation’ i.e. the quantification of that likelihood.

(e)

Environment

Water, including sediment, air, land, wild species of fauna and flora, and any interrelationship between them, as well as any relationship with living organisms.

INTRODUCTION U.K.

1. This Annex lays down principles to ensure that evaluations made and decisions taken by a Member State concerning the authorisation of a biocidal product providing it is a chemical preparation results in a harmonised high level of protection for humans, animals and the environment in accordance with Article 5(1)(b) of this Directive. U.K.

2. In order to ensure a high and harmonised level of protection of human and animal health and of the environment, any risks arising from the use of a biocidal product shall be identified. To achieve this a risk assessment shall be carried out to determine the acceptability or otherwise of any risks identified during the proposed normal use of the biocidal product. This is done by carrying out an assessment of the risks associated with the relevant individual components of the biocidal product. U.K.

3. A risk assessment on the active substance or substances present in the biocidal product is always required. This will already have been carried out for the purpose of Annexes I, IA or IB. This risk assessment shall entail hazard identification, and, as appropriate, dose (concentration) — response (effect) assessment, exposure assessment and risk characterisation. Where a quantitative risk assessment cannot be made a qualitative assessment shall be produced. U.K.

4. Additional risk assessments shall be carried out, in the same manner as described above, on any other substance of concern present in the biocidal product where relevant for the use of the biocidal product. U.K.

5. In order to carry out a risk assessment data are required. These data are detailed in Annexes II, III and IV and, recognising that there are a wide variety of product types, are flexible according to the product type and associated risks. The data required shall be the minimum necessary to carry out an appropriate risk assessment. Member States should take due consideration of the requirements of Articles 12 and 13 of this Directive in order to avoid duplication of data submissions. The minimum set of data required for an active substance in any biocidal product type, however, shall be that detailed in Annex VIIA to Directive 67/548/EEC; these data will already have been submitted and assessed as part of the risk assessment required for entry of the active substance into Annex I, IA or IB to this Directive. Data may also be required on a substance of concern present in a biocidal product. U.K.

6. The results of the risk assessments carried out on an active substance and on a substance of concern present in the biocidal product shall be integrated to produce an overall assessment for the biocidal product itself. U.K.

7. When making evaluations and taking decisions concerning the authorisation of a biocidal product the Member State shall: U.K.

(a)

take into consideration other relevant technical or scientific information which is reasonably available to them with regard to the properties of the biocidal product, its components, metabolites, or residues;

(b)

evaluate, where relevant, justifications submitted by the applicant for not supplying certain data.

8. The Member State shall comply with the requirements of mutual recognition as stated in Articles 4(1), (2) and (6) of this Directive. U.K.

9. It is known that many biocidal products present only minor differences in composition and this should be taken into account when evaluating dossiers. The concept of ‘frame-formulations’ is relevant here. U.K.

10. It is known that certain biocidal products are considered as posing only a low risk, these biocidal products, while complying with the requirements of this Annex, are subject to a simplified procedure as detailed in Article 3 of this Directive. U.K.

11. The application of these common principles shall lead to the Member State deciding whether or not a biocidal product can be authorised, such authorisation may include restrictions on use or other conditions. In certain cases the Member State may conclude that more data are required before an authorisation decision can be made. U.K.

12. During the process of evaluation and decision-making, Member States and applicants shall cooperate in order to resolve any questions on the data requirements quickly or to identify at an early stage any additional studies required, or to amend any proposed conditions for the use of the biocidal product or to modify its nature or its composition in order to ensure full compliance with the requirements of this Annex or of this Directive. The administrative burden, especially for small and medium-sized enterprises (SMEs), shall be kept to the minimum necessary without prejudicing the level of protection afforded to humans, animals and the environment. U.K.

13. The judgments made by the Member State during the evaluation and decision-making process must be based on scientific principles, preferably recognised at international level, and be made with the benefit of expert advice. U.K.

EVALUATION U.K.

General principles U.K.

14. The data submitted in support of an application for authorisation of a biocidal product shall be examined for completeness and overall scientific value by the receiving Member State. After acceptance of these data the Member State shall utilise them by carrying out a risk assessment based on the proposed use of the biocidal product. U.K.

15. A risk assessment on the active substance present in the biocidal product shall always be carried out. If there are, in addition, any substances of concern present in the biocidal product then a risk assessment shall be carried out for each of these. The risk assessment shall cover the proposed normal use of the biocidal product together with a realistic worst-case scenario including any relevant production and disposal issue either of the biocidal product itself or any material treated with it. U.K.

16. For each active substance and each substance of concern present in the biocidal product, the risk assessment shall entail a hazard identification and the establishment of appropriate no-observed-adverse-effect levels (NOAEL), where possible. It shall also include, as appropriate, a dose (concentration) — response (effect) assessment, together with an exposure assessment and a risk characterisation. U.K.

17. The results arrived at from a comparison of the exposure to the no-effect level concentrations for each of the active substances and any substances of concern shall be integrated to produce an overall risk assessment for the biocidal product. Where quantitative results are not available the results of the qualitative assessments shall be integrated in a similar manner. U.K.

18. The risk assessment shall determine: U.K.

(a)

the risk to humans and animals,

(b)

the risk to the environment,

(c)

the measures necessary to protect humans, animals and the general environment during both the proposed normal use of the biocidal product and in a realistic worst-case situation.

19. In certain cases it may be concluded that further data are required before a risk assessment can be finalised. Any such additional data requested shall be the minimum necessary to complete such a risk assessment. U.K.

Effects on humans U.K.

20. The risk assessment shall take account of the following potential effects arising from the use of the biocidal product and the populations liable to exposure. U.K.

21. The effects previously mentioned result from the properties of the active substance and any substance of concern present. They are: U.K.

• acute and chronic toxicity,

• irritation,

• corrosivity,

• sensitisation,

• repeated dose toxicity,

• mutagenicity,

• carcinogenicity,

• reproduction toxicity,

• neurotoxicity,

• any other special properties of the active substance or substance of concern,

• other effects due to physico-chemical properties.

22. The populations previously mentioned are: U.K.

• professional users,

• non-professional users,

• humans exposed indirectly via the environment.

23. The hazard identification shall address the properties and potential adverse effects of the active substance and any substances of concern present in the biocidal product. If this results in the biocidal product being classified according to the requirements of Article 20 of this Directive then dose (concentration) — response (effect) assessment, exposure assessment and risk characterisation shall be required. U.K.

24. In those cases where the test appropriate to hazard identification in relation to a particular potential effect of an active substance or a substance of concern present in a biocidal product has been conducted but the results have not lead to classification of the biocidal product then risk characterisation in relation to that effect shall not be necessary unless there are other reasonable grounds for concern, e.g. adverse environmental effects or unacceptable residues. U.K.

25. The Member State shall apply paragraphs 26 to 29 when carrying out a dose (concentration) — response (effect) assessment on an active substance or a substance of concern present in a biocidal product. U.K.

26. For repeated dose toxicity and reproductive toxicity the dose response relationship shall be assessed for each active substance or substance of concern and, where possible, the no-observed-adverse-effect level (NOAEL) identified. If it is not possible to identify a NOAEL, the lowest-observed-adverse-effect level (LOAEL) shall be identified. U.K.

27. For acute toxicity, corrosivity and irritation, it is not usually possible to derive a NOAEL or LOAEL on the basis of tests conducted in accordance with the requirements of this Directive. For acute toxicity, the LD50 (median lethal dose) or LC50 (median lethal concentration) value or, where the fixed dose procedure has been used, the discriminating dose shall be derived. For the other effects it shall be sufficient to determine whether the active substance or substance of concern has an inherent capacity to cause such effects during use of the product. U.K.

28. For mutagenicity and carcinogenicity it shall be sufficient to determine whether the active substance or substance of concern has an inherent capacity to cause such effects during use of the biocidal product. However, if it can be demonstrated that an active substance or a substance of concern identified as a carcinogen is non-genotoxic, it will be appropriate to identify a N(L)OAEL as described in paragraph 26. U.K.

29. With respect to skin sensitisation and respiratory sensitisation, in so far as there is no consensus on the possibility of identifying a dose/concentration below which adverse effects are unlikely to occur in a subject already sensitised to a given substance, it shall be sufficient to evaluate whether the active substance or substance of concern has an inherent capacity to cause such effects during use of the biocidal product. U.K.

30. Where toxicity data derived from observations of human exposure, e.g. information gained from manufacture, from poison centres or epidemiology surveys, are available special consideration shall be given to those data when carrying out the risk assessment. U.K.

31. An exposure assessment shall be carried out for each of the human populations (professional users, non-professional users and humans exposed indirectly via the environment) for which exposure to a biocidal product occurs or can reasonably be foreseen. The objective of the assessment shall be to make a quantitative or qualitative estimate of the dose/concentration of each active substance or substance of concern to which a population is, or may be exposed during use of the biocidal product. U.K.

32. The exposure assessment shall be based on the information in the technical dossier provided in conformity with Article 8 of this Directive and on any other available and relevant information. Particular account shall be taken, as appropriate, of: U.K.

• adequately measured exposure data,

• the form in which the product is marketed,

• the type of biocidal product,

• the application method and application rate,

• the physico-chemical properties of the product,

• the likely routes of exposure and potential for absorption,

• the frequency and duration of exposure,

• the type and size of specific exposed populations where such information is available.

33. Where adequately measured, representative exposure data are available, special consideration shall be given to them when conducting the exposure assessment. Where calculation methods are used for the estimation of exposure levels, adequate models shall be applied. U.K.

These models shall:

• make a best possible estimation of all relevant processes taking into account realistic parameters and assumptions,

• be subjected to an analysis taking into account possible elements of uncertainty,

• be reliably validated with measurements carried out under circumstances relevant for the use of the model,

• be relevant to the conditions in the area of use.

Relevant monitoring data from substances with analogous use and exposure patterns or analogous properties shall also be considered.

34. Where, for any of the effects set out in paragraph 21 a NOAEL or LOAEL had been identified, the risk characterisation shall entail comparison of the NOAEL or LOAEL with the evaluation of the dose/concentration to which the population will be exposed. Where a NOAEL or LOAEL cannot be established a qualitative comparison shall be made. U.K.

Effects on animals U.K.

35. Using the same relevant principles as described in the section dealing with effects on humans, the Member State shall consider the risks posed to animals from the biocidal product. U.K.

Effects on the environment U.K.

36. The risk assessment shall take account of any adverse effects arising in any of the three environmental compartments — air, soil and water (including sediment) — and of the biota following the use of the biocidal product. U.K.

37. The hazard identification shall address the properties and potential adverse effects of the active substance and any substances of concern present in the biocidal product. If this results in the biocidal product being classified according to the requirements of this Directive then dose (concentration) — response (effect) assessment, exposure assessment and risk characterisation shall be required. U.K.

38. In those cases where the test appropriate to hazard identification in relation to a particular potential effect of an active substance or a substance of concern present in a biocidal product has been conducted but the results have not led to classification of the biocidal product then risk characterisation in relation to that effect shall not be necessary unless there are other reasonable grounds for concern. Such grounds may derive from the properties and effects of any active substance or substance of concern in the biocidal product, in particular: U.K.

• any indications of bioaccumulation potential,

• the persistence characteristics,

• the shape of the toxicity/time curve in ecotoxicity testing,

• indications of other adverse effects on the basis of toxicity studies (e.g. classification as a mutagen),

• data on structurally analogous substances,

• endocrine effects.

39. A dose (concentration) — response (effect) assessment shall be carried out in order to predict the concentration below which adverse effects in the environmental compartment of concern are not expected to occur. This shall be carried out for the active substance and for any substance of concern present in the biocidal product. This concentration is known as the predicted no-effect concentration (PNEC). However, in some cases, it may not be possible to establish a PNEC and a qualitative estimation of the dose (concentration) — response (effect) then has to be made. U.K.

40. The PNEC shall be determined from the data on effects on organisms and ecotoxicity studies submitted in accordance with requirements of Article 8 of this Directive. It shall be calculated by applying an assessment factor to the values resulting from tests on organisms, e.g. LD50 (median lethal dose), LC50 (median lethal concentration), EC50 (median effective concentration), IC50 (concentration causing 50 % inhibition of a given parameter, e.g. growth), NOEL(C) (no-observed-effect level (concentration)), or LOEL(C) (lowest-observed-effect level (concentration)). U.K.

41. An assessment factor is an expression of the degree of uncertainty in extrapolation from test data on a limited number of species to the real environment. Therefore, in general, the more extensive the data and the longer the duration of the tests, the smaller is the degree of uncertainty and the size of the assessment factor. U.K.

The specifications for the assessment factors shall be elaborated in the notes for technical guidance which, to this end, shall be based particularly on the indications given in Commission Directive 93/67/EEC of 20 July 1993 laying down the principles for assessment of risks to man and environment from substances notified in accordance with Council Directive 67/548/EEC(4).

42. For each environmental compartment an exposure assessment shall be carried out in order to predict the concentration likely to be found of each active substance or substance of concern present in the biocidal product. This concentration is known as the predicted environmental concentration (PEC). However in some cases it may not be possible to establish a PEC and a qualitative estimate of exposure then has to be made. U.K.

43. A PEC, or where necessary a qualitative estimate of exposure, need only be determined for the environmental compartments to which emissions, discharges, disposal or distributions including any relevant contribution from material treated with biocidal products are known or are reasonably foreseeable. U.K.

44. The PEC, or qualitative estimation of exposure, shall be determined taking account of, in particular, and if appropriate: U.K.

• adequately measured exposure data,

• the form in which the product is marketed,

• the type of biocidal product,

• the application method and application rate,

• the physico-chemical properties,

• breakdown/transformation products,

• likely pathways to environmental compartments and potential for adsorption/desorption and degradation,

• the frequency and duration of exposure.

45. Where adequately measured, representative exposure data are available, special consideration shall be given to them when conducting the exposure assessment. Where calculation methods are used for the estimation of exposure levels, adequate models shall be applied. The characteristics of these models shall be as listed in paragraph 33. Where appropriate, on a case-by-case basis, relevant monitoring data from substances with analogous use and exposure patterns or analogous properties should also be considered. U.K.

46. For any given environmental compartment, the risk characterisation shall, as far as possible, entail comparison of the PEC with the PNEC so that a PEC/PNEC ratio may be derived. U.K.

47. If it has not been possible to derive a PEC/PNEC ratio, the risk characterisation shall entail a qualitative evaluation of the likelihood that an effect is occurring under the current conditions of exposure or will occur under the expected conditions of exposure. U.K.

Unacceptable effects U.K.

48. Data shall be submitted to and evaluated by the Member State to assess whether the biocidal product does not cause unnecessary suffering in its effect on target vertebrates. This shall include an evaluation of the mechanism by which the effect is obtained and the observed effects on the behaviour and health of the target vertebrates; where the intended effect is to kill the target vertebrate the time necessary to obtain the death of the target vertebrate and the conditions under which death occurs shall be evaluated. U.K.

49. The Member State shall, where relevant, evaluate the possibility of the development of resistance to an active substance in the biocidal product by the target organism. U.K.

50. If there are indications that any other unacceptable effects may occur the Member State shall evaluate the possibility of such effects occurring. An example of such an unacceptable effect would be an adverse reaction to fastenings and fittings used in wood following the application of a wood preservative. U.K.

Efficacy U.K.

51. Data shall be submitted and evaluated to ascertain if the efficacy claims of the biocidal product can be substantiated. Data submitted by the applicant or held by the Member State must be able to demonstrate the efficacy of the biocidal product against the target organism when used normally in accordance with the conditions of authorisation. U.K.

52. Testing should be carried out according to Community guidelines if these are available and applicable. Where appropriate, other methods can be used as shown in the list below. If relevant acceptable field data exist, these can be used. U.K.

• ISO, CEN or other international standard method

• national standard method

• industry standard method (accepted by Member State)

• individual producer standard method (accepted by Member State)

• data from the actual development of the biocidal product (accepted by Member State).

Summary U.K.

53. In each of the areas where risk assessments have been carried out, i.e. effects on man, animals, and the environment, the Member State shall combine the results for the active substance together with the results for any substance of concern to produce an overall assessment for the biocidal product itself. This should take account of any likely synergistic effects of the active substance(s) and substances of concern in the biocidal product. U.K.

54. For biocidal products containing more than one active substance any adverse effects shall also be combined to produce an overall effect for the biocidal product itself. U.K.

DECISION MAKING U.K.

General principles U.K.

55. Subject to paragraph 96, the Member State shall come to a decision regarding the authorisation for use of a biocidal product as a result of the integration of the risks arising from each active substance together with the risks from each substance of concern present in the biocidal product. The risk assessments shall cover normal use of the biocidal product together with a realistic worst-case scenario including any relevant disposal issue either of the biocidal product itself or any material treated with it. U.K.

56. In making a decision concerning authorisation, the Member State shall arrive at one of the following conclusions for each product type and for each area of use of the biocidal product for which application has been made: U.K.

1.

the biocidal product cannot be authorised;

2.

the biocidal product can be authorised subject to specific conditions/restrictions;

3.

more data is required before a decision on authorisation can be made.

57. If the conclusion arrived at by the Member State is that additional information or data are required before an authorisation decision can be made, then the need for any such information or data shall be justified. This additional information or data shall be the minimum necessary to carry out a further appropriate risk assessment. U.K.

58. The Member State shall comply with the principles of mutual recognition as detailed in Article 4 of this Directive. U.K.

59. The Member State shall apply the rules concerning the concept of ‘frame formulations’ when making an authorisation decision on a biocidal product. U.K.

60. The Member State shall apply the rules concerning the concept of ‘low risk’ products when making an authorisation decision on such a biocidal product. U.K.

61. The Member State shall only grant authorisation to those biocidal products which, when used according to their conditions of authorisation, do not present an unacceptable risk to humans, animals or the environment, are efficacious and which contain active substances permitted at Community level to be used in such biocidal products. U.K.

62. The Member State shall impose, where appropriate, conditions or restrictions when giving authorisations. The nature and severity of these shall be selected on the basis of, and be appropriate to, the nature and extent of the expected advantages and the risks likely to arise from the use of the biocidal product. U.K.

63. In the decision-making process the Member State shall take into consideration the following: U.K.

• the results of the risk assessment, in particular the relationship between exposure and effect,

• the nature and severity of the effect,

• the risk management which can be applied,

• the field of use of the biocidal product,

• the efficacy of the biocidal product,

• the physical properties of the biocidal product,

• the benefits of using the biocidal product.

64. The Member State shall, when taking a decision concerning the authorisation of a biocidal product, take into account the uncertainty arising from the variability in the data used in the evaluation and decision-making process. U.K.

65. The Member State shall prescribe that biocidal products shall be used properly. Proper use shall include application at an efficacious dose and minimisation of use of biocidal products where possible. U.K.

66. The Member State shall take the necessary measures to ensure that the applicant proposes a label, and, where relevant, the safety-data sheet, for the biocidal product which: U.K.

• fulfils the requirements of Articles 20 and 21 of this Directive,

• contains the information on the protection of users required by Community legislation on worker protection,

• specifies in particular the conditions or restrictions under which the biocidal product may or may not be used.

Before issuing an authorisation the Member State shall confirm that these requirements must be satisfied.

67. The Member State shall take the necessary measures to ensure that the applicant proposes packaging and, where appropriate, the procedures for destruction or decontamination of the biocidal product and its packaging or any other relevant material associated with the biocidal product, which conforms to the relevant regulatory provisions. U.K.

Effects on humans U.K.

68. The Member State shall not authorise a biocidal product if the risk assessment confirms that, in foreseeable application including a realistic worst possible scenario, the product presents an unacceptable risk to humans. U.K.

69. The Member State shall consider possible effects on all human populations, namely professional users, non-professional users and humans exposed directly or indirectly through the environment when making a decision on the authorisation of a biocidal product. U.K.

70. The Member State shall examine the relationship between the exposure and the effect, and use this in the decision-making process. A number of factors need to be considered when examining this relationship and one of the most important is the nature of the adverse effect of the substance. These effects include acute toxicity, irritancy, corrosivity, sensitisation, repeated dose toxicity, mutagenicity, carcinogenicity, neurotoxicity, reproduction toxicity together with physico-chemical properties, and any other adverse properties of the active substance or substance of concern. U.K.

71. The Member State shall, where possible, compare the results obtained with those obtained from previous risk assessments for an identical or similar adverse effect and decide on an appropriate margin of safety (MOS) when making an authorisation decision. U.K.

An appropriate MOS is typically 100 but an MOS higher or lower than this may be appropriate depending on, among other things, the nature of the critical toxicological effect.

72. The Member State shall, if appropriate, impose, as a condition of authorisation, the wearing of personal protective equipment such as respirators, breathing-masks, overalls, gloves and goggles in order to reduce exposure for professional operators. Such equipment must be readily available to them. U.K.

73. If for non-professional users the wearing of personal protective equipment would be the only possible method for reducing exposure, the product shall not normally be authorised. U.K.

74. If the relationship between the exposure and the effect cannot be reduced to an acceptable level then no authorisation can be given by the Member State for the biocidal product. U.K.

75. No biocidal product classified according to Article 20(1) of this Directive as toxic, very toxic or as a category 1 or 2 carcinogen, or as a category 1 or 2 mutagen, or classified as toxic for reproduction category 1 or 2, shall be authorised for use by the general public. U.K.

Effects on animals U.K.

76. The Member State shall not authorise a biocidal product if the risk assessment confirms that, in normal use, the biocidal product presents an unacceptable risk to non-target animals. U.K.

77. Using the same relevant criteria as described in the section dealing with effects on humans, the Member State shall consider the risks posed to animals from the biocidal product when making an authorisation decision. U.K.

Effects on the environment U.K.

78. The Member State shall not authorise a biocidal product if the risk assessment confirms that the active substance, or any substance of concern, or any degradation, or reaction product presents an unacceptable risk in any of the environmental compartments, water (including sediment), soil and air. This shall include the assessment of risks to non-target organisms in these compartments. U.K.

In considering whether there is an unacceptable risk Member States shall, when coming to a final decision in accordance with paragraph 96, take into account the criteria in paragraphs 81 to 91.

79. The basic tool used in the decision making is the PEC/PNEC ratio or, if this is not available, a qualitative estimation. Due consideration shall be given to the accuracy of this ratio due to variability in the data used both in measurements of concentration and of estimation. U.K.

In the determination of the PEC the most appropriate model should be used taking into account the environmental fate and behaviour of the biocidal product.

80. For any given environmental compartment if the PEC/PNEC ratio is equal to or less than 1 the risk characterisation shall be that no further information and/or testing are necessary. U.K.

If the PEC/PNEC ratio is greater than 1 the Member State shall judge, on the basis of the size of that ratio and on other relevant factors, if further information and/or testing are required to clarify the concern or if risk reduction measures are necessary or if the product cannot be given an authorisation at all. Relevant factors to be considered are those previously mentioned in paragraph 38.

Water U.K.

81. The Member State shall not authorise a biocidal product, if under the proposed conditions of use, the foreseeable concentration of the active substance or of any other substance of concern or of relevant metabolites or breakdown or reaction products in water (or its sediments) has an unacceptable impact on non-target species in the aquatic, marine or estuarine environment unless it is scientifically demonstrated that under relevant field conditions there is no unacceptable effect. U.K.

82. The Member State shall not authorise a biocidal product if, under the proposed conditions of use, the foreseeable concentration of the active substance or of any other substance of concern or of relevant metabolites or breakdown or reaction products in groundwater exceeds the lower of the following concentrations: U.K.

(a)

the maximum permissible concentration laid down by Directive 80/778/EEC, or

(b)

the maximum concentration as laid down following the procedure for including the active substance in Annex I, IA or IB to this Directive, on the basis of appropriate data, in particular toxicological data

unless it is scientifically demonstrated that under relevant field conditions the lower concentration is not exceeded.

83. The Member State shall not authorise a biocidal product if the foreseeable concentration of the active substance or a substance of concern or of relevant metabolites, breakdown or reaction products to be expected in surface water or its sediments after use of the biocidal product under the proposed conditions of use: U.K.

• exceeds, where the surface water in or from the area of envisaged use is intended for the abstraction of drinking water, the values fixed by

  • Council Directive 75/440/EEC of 16 June 1975 concerning the quality required of surface water intended for the abstraction of drinking water in the Member States(5),

  • Directive 80/778/EEC or

• has an impact deemed unacceptable on non-target species

unless it is scientifically demonstrated that under relevant field conditions this concentration is not exceeded.

84. The proposed instructions for use of the biocidal product, including procedures for cleaning application equipment, must be such that the likelihood of accidental contamination of water or its sediments is minimised. U.K.

Soil U.K.

85. Where unacceptable contamination of soil is likely to occur, the Member State shall not authorise a biocidal product if the active substance or substance of concern contained in it, after use of the biocidal product: U.K.

• during tests in the field, persists in soil for more than one year, or

• during laboratory tests, forms non-extractable residues in amounts exceeding 70 % of the initial dose after 100 days with a mineralisation rate of less than 5 % in 100 days,

• has unacceptable consequences or effects on non-target organisms,

unless it is scientifically demonstrated that under field conditions there is no unacceptable accumulation in soil.

Air U.K.

86. The Member State shall not authorise a biocidal product where there is a foreseeable possibility of unacceptable effects on the air compartment unless it is scientifically demonstrated that under relevant field conditions there is no unacceptable effect. U.K.

Effects on non-target organisms U.K.

87. The Member State shall not authorise a biocidal product where there is a reasonably foreseeable possibility of non-target organisms being exposed to the biocidal product if for any active substance or substance of concern: U.K.

• the PEC/PNEC is above 1 unless it is clearly established in the risk assessment that under field conditions no unacceptable effects occur after use of the biocidal product according to the proposed conditions of use, or

• the bioconcentration factor (BCF) related to fat tissues in non-target vertebrates is above 1 unless it is clearly established in the risk assessment that under field conditions no unacceptable effects occur, either directly or indirectly, after use of the product according to the proposed conditions of use.

88. The Member State shall not authorise a biocidal product where there is a reasonably foreseeable possibility of aquatic organisms including marine and estuarine organisms being exposed to the biocidal product if for any active substance or substance of concern in it: U.K.

• the PEC/PNEC is above 1 unless it is clearly established in the risk assessment that under field conditions the viability of aquatic organisms including marine and estuarine organisms is not threatened by the biocidal product according to the proposed conditions of use, or

• the bioconcentration factor (BCF) is greater than 1 000 for substances which are readily biodegradable or greater than 100 for those which are not readily biodegradable unless it is clearly established in the risk assessment that under field conditions no unacceptable impact, either directly or indirectly, occurs on the viability of exposed organisms including marine and estuarine organisms after use of the biocidal product according to the proposed conditions of use.

By way of derogation from this paragraph, Member States may, however, authorise an anti-fouling product used on commercial, public service and naval seagoing vessels for a period of up to 10 years from the date on which this Directive enters into force if similar fouling control cannot be achieved by other practicable means. When implementing this provision, Member States shall, if appropriate, take into account relevant International Maritime Organisation (IMO) resolutions and recommendations.

89. The Member State shall not authorise a biocidal product where there is a reasonably foreseeable possibility of micro-organisms in sewage treatment plants being exposed to the biocidal product if for any active substance, substance of concern, relevant metabolite, breakdown or reaction product the PEC/PNEC ratio is above 1 unless it is clearly established in the risk assessment that under field conditions no unacceptable impact, either directly or indirectly, occurs on the viability of such micro-organisms. U.K.

Unacceptable effects U.K.

90. If the development of resistance to the active substance in the biocidal product is likely the Member State shall take steps to minimise the consequences of this resistance. This may involve modification of the conditions of authorisation or even refusal of any authorisation. U.K.

91. An authorisation for a biocidal product intended to control vertebrates shall not be given unless: U.K.

• death is synchronous with the extinction of consciousness, or,

• death occurs immediately, or,

• vital functions are reduced gradually without signs of obvious suffering.

For repellent products, the intended effect shall be obtained without unnecessary suffering and pain for the target vertebrate.

Efficacy U.K.

92. Member States shall not authorise a biocidal product which does not possess acceptable efficacy when used in accordance with the conditions specified on the proposed label or with other conditions of authorisation. U.K.

93. The level, consistency and duration of protection, control or other intended effects must, as a minimum, be similar to those resulting from suitable reference products, where such products exist, or to other means of control. Where no reference products exist, the biocidal product must give a defined level of protection or control in the areas of proposed use. Conclusions as to the performance of the biocidal product must be valid for all areas of proposed use and for all areas in the Member State except where the proposed label prescribes that the biocidal product is intended for use in specific circumstances. Member States shall evaluate dose response data generated in trials (which must include an untreated control) involving dose rates lower than the recommended rate, in order to assess if the recommended dose is the minimum necessary to achieve the desired effect. U.K.

Summary U.K.

94. In each of the areas where risk assessments have been carried out, i.e. effects on humans, animals, and the environment, the Member State shall combine the conclusions arrived at for the active substance and the substances of concern to produce an overall conclusion for the biocidal product itself. A summary should also be made of the efficacy assessment and of the unacceptable effects. U.K.

The result shall be:

• a summary of the effects of the biocidal product on humans,

• a summary of the effects of the biocidal product on animals,

• a summary of the effects of the biocidal product on the environment,

• a summary of the efficacy assessment,

• a summary of the unacceptable effects.

OVERALL INTEGRATION OF CONCLUSIONS U.K.

95. The Member State shall combine the individual conclusions arrived at with regard to effects of the biocidal product on the three sectors namely, humans, animals and the environment to arrive at an overall conclusion for the global effect of the biocidal product. U.K.

96. The Member State shall then take due consideration of any relevant unacceptable effects, the efficacy of the biocidal product and the benefits of using the biocidal product before taking an authorisation decision on the biocidal product. U.K.

97. The Member State shall ultimately decide whether or not the biocidal product can be authorised and whether this authorisation shall be subject to any restrictions or conditions in conformity with this Annex and this Directive. U.K.

(1)

OJ L 154, 5.6.1992, p. 1.

(2)

OJ L 229, 30.8.1980, p. 11. Directive as last amended by Directive 91/692/EEC (OJ L 377, 31.12.1991, p. 48).

(3)

OJ L 20, 26.1.1980, p. 43.

(4)

OJ L 227, 8.9.1993, p. 9.

(5)

OJ L 194, 25.7.1975, p. 26. Directive as last amended by Directive 91/692/EEC (OJ L 377, 31.12.1991, p. 48).